Marianna Virtanen1,2, Jane E Ferrie3,4, Tasnime Akbaraly3,5,6,7, Adam Tabak3,8, Markus Jokela9, Klaus P Ebmeier10, Archana Singh-Manoux3,11, Mika Kivimäki3,12. 1. Finnish Institute of Occupational Health, Topeliuksenkatu 41 a A, 00250 Helsinki, Finland. marianna.virtanen@ttl.fi. 2. Finnish Institute of Occupational Health, Helsinki, Finland. 3. Department of Epidemiology and Public Health, University College London, United Kingdom. 4. School of Social and Community Medicine, University of Bristol, United Kingdom. 5. Inserm, U1198, Montpellier, France. 6. École Pratique des Hautes Études, Paris, France. 7. Department of Molecular Mechanisms of Neurodegenerative Diseases, University Montpellier, Montpellier, France. 8. First Department of Medicine, Semmelweis University Faculty of Medicine, Budapest, Hungary. 9. Institute of Behavioral Sciences, University of Helsinki, Finland. 10. Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom. 11. Inserm, U1018, AP-HP, Villejuif, France. 12. Department of Public Health, Faculty of Medicine, University of Helsinki, Finland.
Authors: Ricard Navinés; Giovanni Oriolo; Igor Horrillo; Myriam Cavero; Bruno Aouizerate; Martin Schaefer; Lucile Capuron; J Javier Meana; Rocio Martin-Santos Journal: Int J Neuropsychopharmacol Date: 2022-06-21 Impact factor: 5.678